Baseline characteristics | Sample size as above unless stated otherwise in the table | |||
---|---|---|---|---|
BPA treatment type | Total | Statistical significance | ||
Prophylactic (n = 34) | On-demand (n = 13) | n = 47 | p-value* (< 0.05) | |
Gender n (%) | ||||
Male | 34 (100) | 13 (100) | 47 (100) | |
Country, n (%) | ||||
Germany | 20 (59) | 10 (77) | 30 (64) | |
UK | 10 (41) | 3 (23) | 17 (36) | |
Ethnicity, n (%) | ||||
White | 30 (90) | 12 (92) | 42 (90) | |
Black | 3 (9) | 0 (0) | 3 (6) | |
Mixed | 1 (1) | 1 (8) | 2 (4) | |
Age most recent inhibitor (years), mean ± SD | 10.6 ± 4.7 | 10.5 ± 4.1 | 10.6 ± 4.5 | 0.952 |
Family history of an inhibitor, n (%) | n = 33 | n = 13 | n = 46 | |
Yes | 15 (45) | 8 (62) | 23 (50) | 0.326 |
No | 18 (55) | 5 (38) | 23 (50) | |
Bleeding events in last 12 months prior to most recent inhibitor, mean ± SD | n = 31 1.9 ± 1.4 | n = 13 1.4 ± 1.1 | n = 44 1.7 ± 1.2 | 0.349 |
Joint bleeding events in last 12 months prior to most recent inhibitor, mean ± SD | n = 31 1.4 ± 1.4 | n = 13 1.2 ± 1.0 | n = 44 1.3 ± 1.2 | 0.914 |
Target joints, n (%) | ||||
Yes | 31 (91) | 13 (100) | 44 (94) | |
No | 3 (9) | 0 (0) | 3 (6) | 0.369 |
Problem joints, n (%) | ||||
Yes | 31 (91) | 13 (100) | 44 (94) | |
No | 3 (9) | 0 (0) | 3 (6) | 0.369 |
Frequency of target joints, mean ± SD | 6.8 ± 4.3 | 9.1 ± 3.4 | 7.4 ± 4.1 | 0.059 |
Frequency of problem joints, mean ± SD | 6.6 ± 4.3 | 8.6 ± 3.5 | 7.2 ± 4.1 | 0.131 |